The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | JAK1 inhibition enhances pembrolizumab efficacy in PD-L1 positive mNSCLC
Melina Marmarelis, MD, University of Pennsylvania, Philadelphia, PA, discusses a Phase II trial (NCT03425006) of pembrolizumab and short-term itacitinib, a JAK1 inhibitor, in treatment-naïve patients with metastatic non-small cell lung cancer (mNSCLC) with PD-L1 ≥50%. The study showed significant improvement in progression-free survival (PFS) and overall survival (OS) compared to historical data. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
